November 6, 2026

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Keiichi Fujiwara
Interim CFO
TEL: +81-3-5472-1125

Notice Regarding Notice of the Large Volume Exercise of the 70th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment

SymBio Pharmaceuticals Limited (the "Company") hereby announces the large volume exercise of the 70th Stock Acquisition Rights, issued and allotted to EVO FUND on September 2, 2026, during the period from November 2 to November 5, 2026, as below.

1.	Name of Stock Acquisition Rights	SymBio Pharmaceuticals Limited's 70th Stock Acquisition Rights
2.	Number of issued shares from the beginning of the month	8,024,000 shares
3.	Number of stock acquisition rights being exercised from the beginning of the month and the ratio to the entire issue	80,240 rights (Ratio to total number of Stock Acquisition Rights issued 480,000: 16.7%)
4.	Number of Unexercised Stock Acquisition Rights as of the end of the previous month	408,700 rights
5.	Number of unexercised stock acquisition rights as of July 29	328,460 rights

* The ratio of exercised to total issued Stock Acquisition Rights is rounded to one decimal place.

6. Exercise status from the beginning of the month

SymBio Pharmaceuticals Limited's 70th Stock Acquisition Rights

Exercise Date	Number of Shares Delivered		Exercise Price (Yen)	Number of Stock Acquisition Rights Exercised (Rights)
	Newly Issued Shares	Transferred Treasury Shares		
November 2 (Mon)	50,000	-	44	500
November 4 (Wed)	240,000	-	43	2,400
November 5 (Thu)	7,734,000	-	42	77,340

* Number of shares issued as of the end of the previous month: 87,378,960 shares (including 91,394 treasury shares)

For details concerning the Stock Acquisition Rights, please refer to the "Notice Regarding the Execution of an Unsecured Bond Facility Agreement, the Issuance of the 2nd Unsecured Straight Bonds (Private Placement), the Issuance of the 70th and 71st Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment, the Execution of a Purchase Agreement for the Stock Acquisition Rights (Commit Issue), and the Acquisition and Cancellation of the 58th, 66th, and 67th Stock Acquisition Rights" announced on August 17, 2026.